Close Menu

NEW YORK – Cleveland Clinic Innovations (CCI) and Owlstone Medical said today that they are establishing the Center for Early Disease Detection to investigate the use of tests that measure and quantify volatile organic compounds (VOCs) in exhaled breath in combination with noninvasive biomarkers from saliva and blood, among other body fluids. 

Financial and other terms of the collaboration were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.